Harrow Reports Strong Revenue Growth, Narrows Net Loss, and Prepares for Multiple Key Product Launches
Summary
Harrow, Inc. reported strong revenue growth and a significantly reduced net loss for 2025, driven by strategic acquisitions and upcoming product launches, while also improving its debt profile.
Key Events
-
Strong Financial Performance in 2025
Total revenues increased to $272.3 million in 2025 from $199.6 million in 2024. Net loss significantly narrowed to $5.1 million in 2025 from $17.4 million in 2024, and operating cash flow turned positive at $43.8 million, compared to a $22.2 million outflow in the prior year. Cash and cash equivalents rose to $72.9 million at year-end 2025.
-
Strategic Acquisition of Melt Pharmaceuticals
Harrow acquired the remaining equity interests in Melt Pharmaceuticals in November 2025 for an initial cash payment of $4.3 million, with potential contingent payments up to $87.2 million cash and 1.112 million shares upon FDA approval of the MELT-300 product candidate, plus up to $260 million in sales milestones. The MELT-300 NDA submission is expected in H1 2027, with a potential launch in H2 2028.
-
Expansion of Branded Product Portfolio and Pipeline
The company entered a commercialization agreement with Samsung Bioepis in July 2025 for U.S. rights to BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), with launches expected mid-2026 and mid-2027, respectively. Harrow also licensed exclusive U.S. commercial rights to BYQLOVI (clobetasol propionate ophthalmic suspension) in June 2025, with a launch expected mid-2026. Sales teams for VEVYE and IHEEZO are being expanded to target broader ophthalmic procedures.
-
Debt Refinancing and Improved Liquidity
Harrow issued $250 million of 8.625% Senior Notes due 2030 in September 2025, using the proceeds to repay all prior outstanding senior debt, including the Oaktree Loan, 2026 Notes, and 2027 Notes. A new $40 million senior secured revolving credit facility with Fifth Third Bank remains undrawn, enhancing liquidity.
Analysis
Harrow, Inc.'s annual report reveals a significant positive shift in its financial performance and strategic direction. The company achieved substantial revenue growth and dramatically reduced its net loss, moving closer to profitability. Key strategic initiatives, including the acquisition of Melt Pharmaceuticals for its late-stage MELT-300 candidate and commercialization agreements for major biosimilars (BYOOVIZ and OPUVIZ), position Harrow for future growth in the ophthalmic market. The successful refinancing of its debt and securing an undrawn credit facility also significantly improve its liquidity and capital structure. These developments indicate strong operational execution and a clear path for expanding its branded product portfolio.
At the time of this filing, HROW was trading at $46.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $20.85 to $54.85. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.